AI-powered search

Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

Featuring James Del Rosso, DO | Clinical Advisor |

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

| Published April 28, 2022

Loading...

Related Media

Powered by Polaris TM
Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved